TransMedics is facing allegations of fraud, organ trafficking, and unethical practices that have triggered shareholder ...

TransMedics' stock remains under pressure after a weak third quarter, reduced Q4 guidance, the exit of the company's CFO, and ...

TransMedics Group Inc (NASDAQ:TMDX) stock has reached a 52-week low, trading at $58.27, as the company faces a challenging market environment. According to InvestingPro data, the company maintains ...

The law firm of Kirby McInerney LLP is investigating potential claims against TransMedics Group, Inc. (“TransMedics” or the“Company”) (NASDAQ:TMDX). The investigation concerns whether TransMedics ...

LOS ANGELES, CA / ACCESS Newswire / January 16, 2025 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is ...

NEW YORK CITY, NY / ACCESSWIRE / January 15, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on ...

TransMedics Gr TMDX has outperformed the market over the past 5 years by 12.34% on an annualized basis producing an average ...

Shares of TransMedics Group (NASDAQ: TMDX) were tanking 14.3% lower as of 10:46 a.m. ET on Friday. The big sell-off came ...

JP Morgan has recently reduced TransMedics Group Inc (TMDX) stock to Neutral rating, as announced on December 17, 2024, according to Finviz. Earlier, on November 22, 2024, Needham had reduced the ...

NEW YORK CITY, NY / ACCESS Newswire / January 16, 2025 / Pomerantz LLP is investigating claims on behalf of investors of TransMedics Group, Inc. ("TransMedics" or the "Company") (NASDAQ:TMDX). Such ...

TransMedics is a commercial-stage medical technology company working on organ transplant therapy. Check out more about the ...

Shares of Transmedics (NASDAQ: TMDX) fell 28.1% in December, according to data from S&P Global Market Intelligence. On Dec. 2 ...